KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Work In Process (2016 - 2025)

Boston Scientific's Work In Process history spans 17 years, with the latest figure at $246.0 million for Q4 2025.

  • For Q4 2025, Work In Process rose 27.46% year-over-year to $246.0 million; the TTM value through Dec 2025 reached $246.0 million, up 27.46%, while the annual FY2025 figure was $246.0 million, 27.46% up from the prior year.
  • Work In Process for Q4 2025 was $246.0 million at Boston Scientific, roughly flat from $245.0 million in the prior quarter.
  • Across five years, Work In Process topped out at $246.0 million in Q4 2025 and bottomed at $120.0 million in Q1 2021.
  • The 5-year median for Work In Process is $175.5 million (2023), against an average of $175.2 million.
  • The largest annual shift saw Work In Process crashed 34.78% in 2021 before it rose 27.46% in 2025.
  • A 5-year view of Work In Process shows it stood at $128.0 million in 2021, then grew by 14.84% to $147.0 million in 2022, then increased by 18.37% to $174.0 million in 2023, then increased by 10.92% to $193.0 million in 2024, then grew by 27.46% to $246.0 million in 2025.
  • Per Business Quant, the three most recent readings for BSX's Work In Process are $246.0 million (Q4 2025), $245.0 million (Q3 2025), and $218.0 million (Q2 2025).